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Objectives: to investigate the efficacy of levofloxacin in the prevention of vascular prosthetic graft infection in a rat
model.
Methods: graft infections were established in the subcutaneous tissue of 225 male Wistar rats by implantation of Dacron
prostheses followed by topical inoculation with methicillin-susceptible and methicillin-resistant S. epidermidis. The
study included a group without contamination, two contaminated groups without prophylaxis, two contaminated groups
with intraperitoneal levofloxacin prophylaxis, two contaminated groups with intraperitoneal cefazolin prophylaxis, two
contaminated groups with intraperitoneal teicoplanin prophylaxis and six contaminated groups with rifampin-soaked
graft and intraperitoneal levofloxacin, cefazolin or teicoplanin prophylaxis. The grafts were removed after 7 days and
evaluated by quantitative culture.
Results: the efficacy of levofloxacin against the methicillin-susceptible strain was not different to that of cefazolin or
teicoplanin. Levofloxacin showed slight less efficacy than teicoplanin against the methicillin-resistant strain. The
combination levofloxacin-rifampin demonstrated to be similarly effective to the combination rifampin-teicoplanin and
more effective than the combination rifampin-cefazolin against both strains.
Conclusions: rifampin-levofloxacin combination seems useful for the prevention of late-appearing vascular graft infections
caused by S. epidermidis.
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Introduction Materials and Methods
The commercially available methicillin-susceptibleVascular prosthetic graft infection is a dreaded com-
(MS) quality control strain of S. epidermidis ATCC 12228plication of postoperative infection.1–3 Prevention of
and one clinical isolate of methicillin-resistant (MR) S.these infections would have an important impact on
epidermidis (Se62–99) were used.patient mortality and the cost-effectiveness of hospital
Cefazolin, rifampin and oxacillin (all from Sigma-care. Staphylococcus epidermidis, a skin commensal, has
Aldrich S.r.l., Milan, Italy), levofloxacin and teico-emerged as one of the most important pathogens.4
planin (both from Hoechst Marion Roussel, Milan,In addition to antibiotics,4,6 the use of antimicrobials,
Italy) were diluted in accordance with manufacturers’such as rifampin, bound to prosthetic grafts, has been
recommendations yielding 1 mg/ml stock solution.proposed.5,7–13
Solutions of drugs were made fresh on the day ofLevofloxacin is more active than ofloxacin or cipro-
assay or stored at−80°C in the dark for short periods.floxacin against streptococci and staphylococci, and
The concentration range assayed for each antibiotichigher peak concentrations in serum can be achieved
was 0.25–256 mg/l.with the recommended doses.14–19 Because of its antis-
The antimicrobial susceptibilities of the strains weretaphylococcal properties, we investigated the in vivo
determined by using the microbroth dilution method,efficacy of levofloxacin in preventing S. epidermidis late
according to the procedures outlined by the Nationalgraft infection in a rat model.
Committee for Clinical Laboratory Standards.20 The
MIC was taken as the lowest antibiotic concentration at
∗ Please address all correspondence to: A. Giacometti, Clinica Ma-
which observable growth was inhibited. Experimentslattie Infettive, c/o Azienda Ospedaliera Umberto I, Piazza Cappelli,
1, 60121 Ancona, Italy. were performed in triplicate.
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Two-hundred and twenty-five adult male Wistar MIC values were presented as the geometric mean
of three separate experiments. Quantitative culturerats (weight range 300 to 350 g) were studied. The
results were presented as arithmetic mean±standardstudy included a group with no graft contamination
deviation (s.d.). Comparison between quantitative cul-and no antibiotic prophylaxis (uncontaminated con-
ture results were performed by Student t-test. Sig-trol) and two series composed of 7 groups (MS1–7
nificance was accepted when the p value was <0.05.and MR1–7) for each of the staphylococcal strains.
Each of the series included one contaminated group
that did not receive any antibiotic prophylaxis
(treated control), three contaminated groups in which
Resultsperioperative intraperitoneal prophylaxis with levo-
floxacin (10 mg/kg) or cefazolin (30 mg/kg) or teico-
According to the broth-microdilution method, S. epi-planin (10 mg/kg) was administered and three
dermidis ATCC 12228 and S. epidermidis Se62–99 hadcontaminated groups that received rifampin-soaked
MIC values of 0.25 and 0.50 mg/l of levofloxacin. Thegrafted and perioperative intraperitoneal pro-
two strains resulted similarly susceptible to rifampinphylaxis with the above-mentioned agents at the
(MIC values, 0.50 mg/l for both the organisms) andsame concentrations. Rats were anesthetised with
teicoplanin (MIC values, 0.25 mg/l for both the or-ether and their hair of the back was shaved and the
ganisms) while demonstrating different susceptibilityskin cleansed with 10% povidone–iodine solution.
patterns for the betalactams. Actually, S. epidermidisOne subcutaneous pocket was made on each side of
ATCC 12228 was susceptible to oxacillin and cefazolinthe median line by a 1.5 cm incision. Aseptically,
(MIC values 0.5 and 2 mg/l, respectively), while S.1-cm2 sterile collagen-sealed Dacron grafts (Al-
epidermidis Se62–99 was resistant (MIC values 8 andbograftTM, Sorin Biomedica Cardio, S.p.A., Saluggia
32 mg/l, respectively).VC, Italy) were implanted into the pockets. Prior to
None of the animals included in the uncontaminatedimplantation, in the groups MS5–7, and MR5–7, the
control group had anatomic and microbiological evi-Dacron graft segments were impregnated with 5 mg/
dence of graft infection. In contrast, all 30 rats includedml rifampin. Antibiotic bonding was obtained im- in the treated control groups MS1 and MR1 dem-
mediately before implantation by soaking grafts for onstrated evidence of graft infection, with quantitative
20 min in a sterile solution of rifampin. In addition, culture results showing 5.8×106±1.5×106 CFU/ml
the effect of preoperative intraperitoneal levo- and 4.4×106±7.0×105 CFU/ml, respectively.
floxacin, cefazolin and teicoplanin administered For the groups MS2 and MR2 (intraperitoneal
30 min before implantation at the standard dose of levofloxacin) the quantitative graft cultures showed
10, 30 and 10 mg/kg, respectively, was evaluated in bacterial growth (2.7×103±1.6×103 CFU/ml and
the groups MS1–4 and MR1–4. The pockets were 4.0×103±1.7×103 CFU/ml, respectively). Intra-
closed by means of skin clips and sterile saline so- peritoneal teicoplanin showed to be slightly
lution (1 ml) containing S. epidermidis ATCC 12228 or more effective than intraperitoneal levofloxacin
the methicillin-resistant strain S. epidermidis Se62–99 (2.9×102±1.1×102 CFU/ml, and 4.6×102±1.6×102
at a concentration of 2×107 cfu/ml was inoculated CFU/ml, respectively). Cefazolin exhibited an activity
onto the graft surface by using a tuberculin syringe similar to that of levofloxacin only for S. epidermidis
to create a subcutaneous fluid-filled pocket.3 The ATCC 12228 (4.6×103±2.0×103 CFU/ml), while there
animals were returned to individual cages and thor- was less efficacy against S. epidermidis Se62–99
oughly examined daily. All grafts were explanted at (3.6×106±9.8×105 CFU/ml). The groups MS5 and
7 days following implantation. MR5 (rifampin-soaked Dacron grafts plus intra-
The explained grafts were placed in sterile tubes, peritoneal levofloxacin) and the groups MS7 and MR7
washed in sterile saline solution, placed in tubes con- (rifampin-soaked Dacron grafts plus intraperitoneal
taining 10 ml of phosphate-buffered saline solution teicoplanin) showed no evidence of staphylococcal
and sonicated for 5 min to remove the adherent bac- infection, with negative quantitative cultures. Finally,
teria from the grafts. Quantitation of viable bacteria the results from the association rifampin-cefazolin
was performed by culturing serial dilutions (0.1 ml) (groups MS6 and MR6) demonstrated to be less effect-
of the bacterial suspension on blood agar plates. All ive than the above-mentioned combination. Actually in
plates were incubated at 37°C for 48 h and evaluated MS6 and MR6 groups the infection occurred, although
for the presence of the staphylococcal strains. The with low bacterial numbers (2.4×103±0.6×103 CFU/
organisms were quantitated by counting the number ml and 4.9×103±1.2×103 CFU/ml, respectively). The
results are summarised in Table 1.of colony-forming units (CFUs) per plate.
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Table 1. Quantitative microbiological results of the in vivo experiments.
Groupa Graft-bonded drugb Intraperitoneal Quantitative graft
preoperative drugc culture (CFU/ml)
Control — — 0.0
MS1 — — 5.8×106±1.5×106
MS2d — Levofloxacin 2.7×103±1.6×103
MS3d — Cefazolin 4.6×103±2.0×103
MS4d — Teicoplanin 2.9×102±1.1×102
MS5de Rifampin Levofloxacin 0.0
MS6d Rifampin Cefazolin 2.4×103±0.6×103
MS7de Rifampin Teicoplanin 0.0
MR1 — — 4.4×106±7.0×105
MR2f — Levofloxacin 4.0×103±1.7×103
MR3f — Cefazolin 3.6×106±9.8×105
MR4f — Teicoplanin 4.6×102±1.6×102
MR5f Rifampin Levofloxacin 0.0
MR6f Rifampin Cefazolin 4.9×103±1.2×103
MR7fg Rifampin Teicoplanin 0.0
a Each group was formed by 15 animals; MS1–7, groups of animals infected with methicillin-susceptible
S. epidermidis ATCC 12228; MR1–7, groups of animals infected with methicillin-resistant S. epidermidis Se
62–99.
b The Dacron graft segments were impregnated with 5 mg/ml rifampin
c Levofloxacin 10 mg/kg; cefazolin, 30 mg/kg; teicoplanin 10 mg/kg.
d Statistically significant when compared with group MS1.
e Statistically significant when compared with group MS2, MS3, MS4, and MS6.
f Statistically significant when compared with groups MR1.
g Statistically significant when compared with groups MR2, MR3, MR4, and MR6.
There were significant differences in the results from about the need for other antibiotics to use in pro-
the quantitative bacterial graft cultures when the data phylactic regimens.21–24 During the past decade, there
obtained from the groups MS2, MS3, MS4, MS5 MS6 has been continued interest in improving the anti-
and MS7 were compared with those obtained from bacterial activities of fluorinated quinolones. However,
the untreated MS1 group (p<0.01). Similarly, when the the emergence of ciprofloxacin-resistant staphylococci
data obtained from the groups MR2, MR4, MR5, MR6 has been reported with increasing frequency.25–27 Sev-
and MR7 were compared with those obtained from eral studies showed that levofloxacin had greater in
MR1, the differences were statistically significant vitro and in vivo anti-staphylococcal activity than the
(p<0.01). Moreover, in spite of the high bacterial num- other fluoroquinolones such as ofloxacin or ci-
bers obtained by the quantitative cultures from the profloxacin.14,15,17 Moreover, it has been shown that this
group MR3, the difference remained significant when agent selects for resistance at a lower frequency than
the comparison was carried out between the groups ciprofloxacin. In this study, levofloxacin showed sim-
MR1 and MR3 (p=0.02). Finally, the quantitative bac- ilar in vitro activity against S. epidermidis ATCC 12228
terial cultures showed significant differences when the than cefazolin, which was more active against the
groups MS5 and MS7 were compared with the other other strain. Interestingly, it exhibited only a slight
MS-groups (p<0.01) and, similarly, when the groups less activity than teicoplanin against the two sta-
MR5 and MR7 were compared with the other MR- phylococcal strains. Finally, the combination of levo-
groups (p<0.01). floxacin with rifampin was demonstrated to be
similarly effective to the combination of rifampin and
teicoplanin and more effective than the combination
of rifampin and cefazolin against both strains. TheseDiscussion
results were generally in agreement with those re-
ported by other investigators, showing that levo-Cephalosporins have often been used for perioperative
floxacin was active against methicillin-susceptibleprophylaxis but, after the initial success, resistance to
and -resistant staphylococci, even though teicoplanin,these drugs began to emerge. Since the emergence of
when used alone, had more anti-staphylococcal ac-methicillin-resistant staphylococci glycopeptides have
tivity.14,15,17 The animal model used in the present studybeen administered as an alternative and effective treat-
is not directly comparable with graft implantation intoment for staphylococcal infections. However, the
a blood-vessel, and caution is needed to compare theserecent emergence of glycopeptide resistance in co-
agulase-negative staphylococci heightens concerns results with the real situation of an implanted graft in
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no development of rifampicin resistance in an animal model.the aorta of a living human being. Nevertheless, taken
Eur J Vasc Endovasc Surg 1995; 9: 314–318.
together, the results of this study demonstrated that the 11 Shue WB, Worosilo SC, Donetz AP et al. Prevention of vascular
prosthetic infection with an antibiotic-bonded Dacron graft. Juse of rifampin-coated Dacron graft plus perioperative
Vasc Surg 1988; 8: 600–605.intraperitoneal teicoplanin or levofloxacin can result
12 Vicaretti M, Hawthorne WJ, Ao PY, Fletcher JP. An increased
in significant bacterial growth inhibition even if high concentration of rifampicin bonded to gelatin-sealed Dacron
reduces the incidence of subsequent graft infections following aconcentrations of organisms are topically inoculated
staphylococcal challenge. Cardiovasc Surg 1998; 6: 268–273.on the Dacron prostheses. Finally, similarly to the 13 Yamamura K, Sakurai T, Yano K, Osada T, Nabeshima T.
other agents, levofloxacin did not show a noteworthy Prevention of vascular graft infection by sisomicin incorporated
into fibrin glue. Microbiol Immunol 1995; 39: 895–896.toxicity: none of the animals included in any group
14 Chambers HF, Xiang Liu Q, Liuxin Chow L, Hackbarth C.died or had clinical evidence of drug-related adverse Efficacy of levofloxacin for experimental aortic-valve endo-
effects, such as local signs of perigraft inflammation, carditis in rabbits infected with viridans group streptococcus
or Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43:anorexia, vomiting, diarrhoea, and behavioural al-
2742–2746.
terations. Further investigations are required to define 15 Von Eiff C, Peters G. In-vitro activity of ofloxacin, levofloxacin
and D-ofloxacin against staphylococci. J Antimicrob Chemotherthe role of levofloxacin as prophylactic agent in the
1996; 38: 259–263.prevention of late-appearing vascular prosthetic graft
16 Biedenbach DJ, Jones RN. The comparative antimicrobial ac-
infections. tivity of levofloxacin tested against 350 clinical isolates of strep-
tococci. Diagn Microbiol Infect Dis 1996; 25: 47–51.
17 Smith SM, Eng HK, Tecson-Tumang F. Ciprofloxacin therapy
for methicillin-resistant Staphylococcus aureus infections or col-
onizations. Antimicrob Agents Chemother 1989; 33: 181–184.
18 Pfaller MA, Jones RN. Comparative antistreptococcal activity
of two newer fluoroquinolones, levofloxacin and sparfloxacin.References
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